fda compounding semaglutide enforcement november 2025 Diabetes advocacy group discourages use of compounded GLP-1 drugs fda semaglutide compounding enforcement november

It may also increase the risk of hypoglycaemia when taken alongside sulphonylureas or insulin, so your prescribing clinician should review your full medication list before and during treatment

Additionally, hypersensitivity reactions occurred in approximately 2-4% of participants

The takeaway for anyone researching timelines: the gap between the 24-week and 48-week readings was substantial, and the curve was still moving at the end

This limitation led researchers to explore therapies targeting multiple metabolic pathways

As a result, these claims are false or misleading and your products are therefore misbranded. Why This Matters Together, these developments signal renewed enforcement of drug approval and safety standards, alongside aggressive protection of pharmaceutical intellectual property